首页 | 本学科首页   官方微博 | 高级检索  
检索        

不同剂量阿托伐他汀钙对稳定型心绞痛患者S100A12、hs-CRP的影响
引用本文:刘亚洋,李鹤.不同剂量阿托伐他汀钙对稳定型心绞痛患者S100A12、hs-CRP的影响[J].实用药物与临床,2017(1):48-52.
作者姓名:刘亚洋  李鹤
作者单位:1. 江苏省淮安市第二人民医院心内科,江苏淮安,223002;2. 江苏省淮安市中医院心内科,江苏 淮安,223001
摘    要:目的研究稳定型心绞痛患者经过不同剂量阿托伐他汀治疗后炎症因子S100A12、hs-CRP的变化。方法正常对照组(对照组)90例;稳定型心绞痛患者180例,随机分为阿托伐他汀10 mg治疗组(10 mg组,90例)和阿托伐他汀20 mg治疗组(20 mg组,90例)。在标准化治疗基础上,10 mg组和20 mg组患者分别给予阿托伐他汀10、20 mg/d,检测治疗前及治疗后6、12周三组患者的S100A12、hs-CRP水平。结果 10 mg组及20 mg组S100A12、hs-CRP水平均显著高于对照组(P<0.001)。10 mg组、20 mg组患者治疗6、12周后,S100A12、hs-CRP均较治疗前显著下降;治疗12周较治疗后6周进一步下降,差异均有统计学意义(P<0.001)。治疗后6周,20 mg组S100A12、hs-CRP水平较10 mg组下降更明显(P=0.002,P=0.042)。治疗后12周,20 mg组S100A12、hs-CRP水平较10 mg组下降更明显(P<0.001)。治疗后,20 mg组S100A12、hs-CRP血清水平降幅较10 mg组更显著,差异有统计学意义(P<0.001)。S100A12、hs-CRP水平存在相关性(r=0.663,P<0.001)。10 mg组、20 mg组治疗前后S100A12、hs-CRP水平差值呈正相关关系(r=0.275,P=0.009)。结论阿托伐他汀可使稳定型心绞痛患者S100A12、hs-CRP血清水平下降,具有抗炎作用。

关 键 词:阿托伐他汀  稳定型心绞痛  S100A12  hs-CRP

Effects of different doses of atorvastatin calcium on S100 A12 and hs-CRP in pa tients with stable angina pectoris
LIU Ya-yang,LI He.Effects of different doses of atorvastatin calcium on S100 A12 and hs-CRP in pa tients with stable angina pectoris[J].Practical Pharmacy and Clinical Remedies,2017(1):48-52.
Authors:LIU Ya-yang  LI He
Abstract:Objective To investigate the effects of different doses of atorvastatin therapy on the levels of S100A12 and hypersensitive C-reactive protein (hs-CRP) in patients with stable angina pectoris (SAP). Methods Ninty cases were included in normal control group ( control group);180 cases of SAP patients were randomized into atorvastatin 10 mg group (10 mg group,n=90) and atorvastatin 20 mg group (20 mg group,n=90). Based on stand-ard treatment,patients in 10 mg group and 20 mg group were given atorvastatin 10 mg/d and 20 mg/d taken orally. The levels of S100A12 and hs-CRP of the three groups were measured before and 6 and 12 weeks after treatment. Results The concentration of serum S100A12 and hs-CRP in 10 mg group and 20 mg group was significantly higher than that of control group (P<0. 001). At 6 and 12 weeks after treatment,the serum levels of S100A12 and hs-CRP in 10 mg group and 20 mg group were significantly lower than before treatment,and it was much lower at 12 weeks after treat-ment (P<0. 001);At 6 weeks after treatment,the level of serum S100A12 and hs-CRP in 20 mg group decreased more significantly than that of 10 mg group (P =0. 002,P =0. 042). After treatment of 12 weeks,the levels of serum S100A12 and hs-CRP in 20 mg group decreased more significantly than those of 10 mg group (P<0. 001). The de-cline values of S100A12 and hs-CRP serum before and after treatment in 20 mg group were more significant than those of 10 mg group (P <0. 001). Linear correlation analysis showed that S100A12 level was related to hs-CRP (r =0. 663,P<0. 001). The differences of S100A12 levels before and after treatment were positively correlated with those of hs-CRP levels before and after treatment in 10 mg group and 20 mg group(r=0. 275,P=0. 009). Conclusion Atorvastatin can reduce the concentration of S100A12 and hs-CRP in SAP with anti-inflammation effects.
Keywords:Atorvastatin  Stable angina pectoris  S100A12  hs-CRP
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号